Benzinga | Mar 24, 2021 07:04AM EDT

Oppenheimer Maintains Outperform on aTyr Pharma, Raises Price Target to $14

Oppenheimer analyst Hartaj Singh maintains aTyr Pharma (NASDAQ:LIFE) with a Outperform and raises the price target from $12 to $14.